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Gene  modiﬁcations  in the  PmrAB  and  PhoPQ  two-component  regulatory  systems,  as  well  as inactivation
of  the  mgrB  gene,  are  known  to be  causes  of colistin resistance  in Klebsiella pneumoniae.  The  objective
of  this  study  was  to characterise  the  mechanism  involved  in colistin  resistance  in a  Klebsiella  oxytoca
isolate.  A  K. oxytoca  clinical  isolate  showing  resistance  to  colistin  was  recovered  in  Cali, Colombia.  The
pmrA,  pmrB,  phoP,  phoQ  and  mgrB  genes  were  ampliﬁed  and  sequenced.  Wild-type  mgrB  genes  from  K.
pneumoniae  and  K. oxytoca  were  cloned,  and  corresponding  recombinant  plasmids  were  used  for  com-
plementation  assays.  By  analysing  the  mgrB  gene  of the  K. oxytoca  isolate  and  its  ﬂanking  sequences,
an  insertion  sequence  (IS) of 1196  bp  was  identiﬁed  in its promoter  region.  The  insertion  was  located
between  nucleotides  −39  and  −38  when  referring  to  the  start  codon  of the  mgrB  gene,  thus  negatively
interfering  with  expression  of the  mgrB  gene  by  modifying  its  promoter  structure.  This  IS  was  very  simi-
lar  to ISKpn26  (99%  nucleotide  identity)  belonging  to the  IS5  family.  Complementation  assays  with  mgrB
genes  from  wild-type  K. pneumoniae  or  K. oxytoca  restored  full  susceptibility  to colistin.  In  conclusion,
here  we identiﬁed  the  mechanism  involved  in colistin  resistance  in a K. oxytoca  isolate.  Modulation  of
mgrB  gene  expression  was  the  key  factor  for  this acquired  resistance  to colistin.
1. Introduction
Klebsiella oxytoca and Klebsiella pneumoniae are  frequent
sources of nosocomial infections and the sources of nosocomial
outbreaks [1,2]. The occurrence of multidrug resistance is  increas-
ingly observed among the Gram-negative pathogens Acinetobacter
baumannii, Pseudomonas aeruginosa and Enterobacteriaceae. Con-
sequently, use of colistin, a  polymyxin-type antibiotic, is  being
reconsidered in particular for treating critically ill patients infected
with these pathogens [3–5]. Unfortunately, the increasing usage of
colistin is being associated with the emergence of colistin resis-
tance, in particular in K. pneumoniae [6–11].
Alterations in the two-component regulatory systems PmrAB
and PhoPQ [8,9,12] are known to  be involved in  polymyxin
resistance in K. pneumoniae. Inactivation of the mgrB gene,
∗ Corresponding author. Tel.: +41 26  300  9582.
E-mail  address: laurent.poirel@unifr.ch (L. Poirel).
encoding a  negative feedback regulator of the PhoPQ two-
component system, is also a common mechanism involved in
colistin resistance in K.  pneumoniae [10,13]. The reported alter-
ations in the mgrB gene include insertion of several insertions
sequences (IS5-like, IS1F-like, ISKpn13, ISKpn14) at different loca-
tions in the coding sequence of mgrB and in its promoter
region. Non-silent point mutations, premature stop codons, small
intragenic deletions and large deletion of the mgrB locus are
also known. These alterations result in  either reduced or  even
lack of expression of the mgrB gene leading to upregulation of
the phoPQ and pmrHFIJKLM operons that confer resistance to
colistin.
Lippa and Goulian have identiﬁed MgrB homologues in the
genome sequences of various enterobacterial species [14]. There-
fore, alterations in  mgrB gene expression might possibly be
involved in acquisition of colistin resistance in  different Klebsiella
species.
The aim of this study was  to  identify the mechanism responsible
for resistance to  colistin in a  K.  oxytoca clinical isolate.
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2. Materials and methods
2.1.  Bacterial strain
The  colistin-resistant K. oxytoca clinical isolate was  iden-
tiﬁed using an API20E system and the matrix-assisted laser
desorption/ionisation time-of-ﬂight (MALDI-TOF) technique (AB
bioMérieux, La Balme-les-Grottes, France). A colistin-susceptible
K. oxytoca clinical isolate was used as a  wild-type control.
2.2.  Antimicrobial susceptibility
Antimicrobial  susceptibility testing was performed using Etest
strips (AB bioMérieux) on Mueller–Hinton agar plates (Bio-Rad,
Marnes-la-Coquette, France) with a  0.5 McFarland inoculum.
Minimum inhibitory concentrations (MICs) were interpreted as
indicated by the European Committee on Antimicrobial Sus-
ceptibility Testing (EUCAST) guidelines (Breakpoint tables for
interpretation of MICs and zone diameters. Version 4.0, 2014;
http://www.eucast.org). Isolates with colistin MICs of ≤2  g/mL
were  categorised as susceptible whereas those with MICs of
>2 g/mL were resistant.
2.3. PCR ampliﬁcation and sequencing
Whole-cell DNA was extracted using a  QIAquick Kit (QIAGEN,
Courtaboeuf, France) according to  the manufacturer’s instructions.
The entire pmrA, pmrB, phoP, phoQ and mgrB genes were ampli-
ﬁed with speciﬁc oligonucleotides primers (Table 1) designed
with sequences of K. oxytoca KCTC 1686 and E718 genomes avail-
able on the National Center for Biotechnology Information (NCBI)
database (http://www.ncbi.nlm.nih.gov.gate2.inist.fr/). Ampliﬁed
DNA fragments were puriﬁed with a  QIAquick PCR Puriﬁcation Kit
(QIAGEN). Both strands of the ampliﬁcation products obtained were
sequenced with an ABI 3100 Sequencer (Applied Biosystems, Fos-
ter City, CA). The nucleotide and deduced protein sequences were
analysed at the NCBI website (http://www.ncbi.nlm.nih.gov) by the
Basic  Local Alignment Search Tool (BLAST) programme. The inser-
tion sequence (IS) was analysed using the IS ﬁnder website (http://
www-is.biotoul.fr).
2.4. Complementation assays
The wild-type mgrB gene from a colistin-susceptible K. oxytoca
strain and a K. pneumoniae strain, as well as the non-coding mdh
sequence [15], were ampliﬁed by PCR using 2X Phusion® HF Mas-
ter Mix  (Finnzymes; Life Technologies, Illkirch, France) and the
primers listed in Table 1. The ampliﬁed fragments were cloned
into the plasmid pCR®-Blunt II-TOPO® (Invitrogen, Illkirch, France)
Table 1
Primers used in this study.
Primer Sequence (5′–3′)  Gene Ref.
Kox pmrC ext F GCC GAT ATC GCA GGG GTT AA pmrC This study
Kox pmrC ext R TAA CAG GAG CGC ATC GTC TT pmrC
Kox  pmrA ext F GCA AGC GTA TTC GCA GGA TA pmrA
Kox  pmrA ext R CTG ATG AGC TGA CAA ACG GC pmrA
Kox  pmrB ext F CAA CGA CAT TTA CAG CTG GG pmrB
Kox  pmrB ext R CTT TAC TGA GGA TAG CGC CA pmrB
Kox  phoP ext F CCA AGA GAC CGA GGT ACA AA phoP
Kox  phoP ext R GAG TGA CAA CAC CAG CAC  TA phoP
Kox  phoQ ext F CCA TAC CAT CGA TGT GCT GA phoQ
Kox  phoQ ext R GCA GGT GTC TGT TAG GGA TT phoQ
Kox  mgrB ext F CGC GGT TTA AGA AGG TCA TG mgrB
Kox  mgrB ext R AGG CGT TTA TTC TAC CAC CC  mgrB
mdh  F CCC AAC TCG CTT CAG GTT CAG mdh [15]
mdh R CCG TTT TTC CCC AGC AGC AG mdh
and the resulting plasmids pTOPO-mgrBKox, pTOPO-mgrBKp and
pTOPO-mdh (encoding resistance to ZeocinTM) were respectively
transformed into an electrocompetent colistin-resistant K.  oxy-
toca isolate by electroporation. Electrotransformants were selected
by overnight incubation at 37 ◦C on Mueller–Hinton agar supple-
mented with 100 g/mL ZeocinTM.  MICs of colistin for the K. oxytoca
transformants were determined by Etest (bioMérieux).
3. Results and discussion
3.1.  Strain and patient features
The  colistin-resistant K.  oxytoca isolate C24 was  recovered
in February 2008 from a  soft-tissue secretion from a  66-year-
old male patient hospitalised for an intra-abdominal infection
in Cali, Colombia. The isolate was  resistant to broad-spectrum
cephalosporins (MICs of ceftazidime and cefotaxime =  32 g/mL),
amikacin (MIC = 16 g/mL) and colistin (MIC =  24 g/mL) and was
of intermediate susceptibility to ciproﬂoxacin (MIC = 1 g/mL).
The isolate was susceptible to  carbapenems (MIC <  0.5  g/mL),
gentamicin (MIC =  0.5 g/mL) and tigecycline (MIC = 0.5 g/mL). It
harboured a blaCTX-M-15 gene but did not produce any carbapene-
mase according to the Carba NP test. To our  knowledge, the patient
had never been treated with any polymyxin.
3.2. Modiﬁcation of mgrB gene expression through insertion of
an  insertion sequence element
Sequence analysis of the pmrA, pmrB, phoP and phoQ genes
known to be involved in lipopolysaccharide (LPS) synthesis showed
100% identity with the genes identiﬁed from colistin-susceptible
wild-type K.  oxytoca isolates (data not shown). Sequence analysis of
the mgrB gene as well as upstream-located sequences revealed that
an IS of 1196 bp had targeted the upstream vicinity of the mgrB gene
between nucleotides −38 and −39 when referring to the start codon
of mgrB. This IS was similar to ISKpn26 (differing by only 5 bp) and
belonged to  the IS5 family. It was  bracketed by a  4-bp duplication
(TTAT) being the likely signature of a  transposition process. The ori-
gin of ISKpn26 is K. pneumoniae (https://www-is.biotoul.fr/index.
html?is  special name=ISKpn26)  and it has also been identiﬁed in
K.  oxytoca KONIH1 (GenBank accession no. CP008788.1). In silico
analysis of the sequence located upstream of a wild-type mgrB gene
revealed a putative promoter sequence made of −35 [TTGAAA]
and −10 [TAAACT] boxes separated by 15 bp (Fig. 1). Insertion of
ISKpn26 in  isolate C24 led  to  displacement of this promoter with
respect to the mgrB gene position, the corresponding −35 and −10
sequences being consequently very distant from it (Fig. 1). This sug-
gests a  decrease or even lack of expression of the mgrB gene, leading
to low or absence of production of the corresponding protein and
consequently to acquired resistance to colistin.
3.3. Complementation experiments
To conﬁrm whether higher expression of mgrB might restore
susceptibility to  colistin, complementation of isolate C24 with
a plasmid overexpressing mgrB was performed. Transformation
assays were either performed with plasmids encoding the MgrB
protein of K. oxytoca or K. pneumoniae, respectively. The mgrB gene
was provided in trans together with its original promoter in order
to ensure it would be expressed at a wild-type level. Following
complementation, isolate C24 recovered full susceptibility to
colistin with the wild-type MgrB of K.  oxytoca (MIC =  0.047 g/mL).
Interestingly, the same MIC  was obtained after complementation
with the MgrB of K. pneumoniae (MIC =  0.047 g/mL). As expected,
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TGAACATCGTTTGAA ACAAGTC TATGA TTCCTA AAC TTGCCT TTCG TATTACAG TTAGC CGCGGT T 
      –35   PROM         –10 
         ISKpn26-li ke 
TAAG AAGGTC ATGTT ATCCTGG CGACATCT GGTACT GATGCGGAGTGTGGAGTG
 mgrB start co don
Fig. 1. Sequences located at the 5′-extremity of the mgrB gene. The  putative promoter (PROM) is  indicated, with its respective −35  and −10 boxes underlined. The arrow
indicates the target site for insertion of the insertion sequence ISKpn26-like. The  mgrB start codon is in bold.
transformation with plasmid pTOPO-mdh used as a negative
control did not restore susceptibility to colistin (MIC = 24 g/mL).
3.4.  Comparison of mgrB gene sequences of K. oxytoca and K.
pneumonia
Alignment of the mgrB sequences from wild-type K.  pneumo-
niae MGH78578 and K. oxytoca KCTC1686 strains showed that
the sequences were almost identical [only a  single amino acid
substitution (Cys to Tyr at amino acid position 28)]. This result
explains why complementation with the mgrB gene of K. pneumo-
niae restored full susceptibility to  colistin in  the K.  oxytoca isolate.
Furthermore, it may  suggest that all previously reported alterations
of the mgrB gene [10,13] that have been shown to be  the sources
of acquired resistance to colistin in  K. pneumoniae (such as inser-
tions of IS elements at different locations in the coding sequence
of mgrB, non-silent point mutations, premature stop codons, intra-
genic deletions, etc.) might also be a source of colistin resistance in
K. oxytoca.
4. Conclusion
This study reports on the molecular identiﬁcation of colistin
resistance in K. oxytoca. This resistance mechanism is associated
with modiﬁcation of the biosynthesis pathway of LPS. It  is simi-
lar to that reported in K.  pneumoniae, underlining that common
mechanisms of colistin resistance could be identiﬁed in different
enterobacterial species.
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